Treatment and Fate in Fistulizing Crohn's Disease in a Pediatric Population

NCT ID: NCT05759104

Last Updated: 2023-03-08

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-01-01
• Study Completion Date: 2023-07-01

Brief Summary

Crohn's disease is a inflammatory bowel disease evolving towards the destruction of the intestinal wall resulting in stenosing or perforating complications (fistulas, abscesses).

The treatment of perforating Crohn's disease is not codified.

Detailed Description

The old dogmas leading to surgery after failure of medical treatment have recently been overturned, particularly since the advent of anti-TNFs.

Biotherapies now have a central place, including for complicated forms. Previous studies have already looked at the usefulness of anti-TNFs in stenosing forms, or concerning ano-perineal lesions, but what about digestive fistulas.

Indeed, data are scarce, especially in paediatrics.

Conditions

Crohn Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Interventions

Infliximab

Drug

Intervention Type: DRUG

Stomy

Surgery

Intervention Type: PROCEDURE

Other Intervention Names

Adalimumab; Ustékinumab; Resection

Eligibility Criteria

Inclusion Criteria

• Minor patients (aged 3 to 18).
• Diagnosed with Crohn's disease.
• fistulizing crohn's disease

Exclusion Criteria

• perianal crohn disease

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Central Hospital, Nancy, France

OTHER

Sponsor Role: lead

Responsible Party

CHABOT Caroline

Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

2022PI067

Identifier Type: -

Identifier Source: org_study_id